Vivus (NASDAQ: VVUS) is a small pharmaceutical company headquartered in Campbell, California, working in obesity, sleep, and sexual health. Vivus is developing an erectile dysfunction drug, Avanafil, that has completed Phase 3 clinical trials. The drug has been approved for use by the FDA, and will be sold under the trademark name Stendra. Stendra is the first and only oral ED treatment approved to be taken approximately 15 minutes before sexual activity.
Vivus also developed an obesity drug, Qnexa (now called Qsymia), a combination of phentermine and topiramate, two existing weight-loss drugs. On July 17, 2012, The U.S. Food and Drug Administration approved Qsymia (phentermine and topiramate extended-release), made by Vivus, as an addition to a reduced-calorie diet and exercise for chronic weight management. The drug was approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).
- Phase 3 Data on VIVUS' Avanafil for Erectile Dysfunction to be Featured at the AUA 2010 Annual Meeting, ""
- "Most Popular in Your Life". USA Today.
- "VIVUS and Auxilium Announce Stendra Label Expansion". Zacks Investment Research.
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP), ""
- Hellmich, Nancy (17 July 2012). "New diet drug helps patients lose about 10% of weight". USA Today. Retrieved 17 July 2012.
- "Medications Target Long-Term Weight Control". FDA.gov. Retrieved 17 July 2012.
- "2016 Winners by rank" (PDF). Deloitte. Retrieved 14 October 2017.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|